Effect of G17DT in Patients With Stage II/III Colorectal Cancer

Colorectal Cancer Clinical Trial

— CC5  

Official title:

An Open-label Volunteer Study of the Effect of G17DT on the Elevation of Plasma Gastrin Levels After Therapy With a Proton Pump Inhibitor (Omeperazole) in Patients With Treated Stage II/III Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02518373
• Other study ID #: CC5
• Status: Completed
• Phase: Phase 2
• First received: August 4, 2015
• Last updated: August 5, 2015
• Start date: April 2000
• Est. completion date: February 2001

Study information

• Verified date: August 2015
• Source: Cancer Advances Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This Phase 2 study was an open label, single-center 18-week study to compare basal and meal stimulated plasma gastrin levels before and after treatment with 3 intramuscular injections of 250 µg G17DT, with and without the concomitant administration of Omeprazole.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: February 2001
• Est. primary completion date: February 2001
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female subjects aged 18 to 70 years, inclusive

• Written informed consent was provided

• Histologically confirmed Stage II/III colorectal cancer after radical surgery

• A minimum of 3 months elapsed since completion of the chemotherapy for subjects who had received adjuvant chemotherapy

• Subject had recovered from any toxic effects of chemotherapy

Exclusion Criteria:

• Had a known local recurrence of colorectal cancer or presence of metastatic colorectal cancer lesions

• Was using an inadequate method of contraception (determined at the discretion of the investigator), only for women of childbearing potential who were sexually active

• Was unable to comply with the protocol

• Was unable to abstain from H2 receptor antagonists, PPIs or anticholinergics medications for 2 weeks

• Required H. pylori eradication therapy during the study

• Had prior vaccination with G17DT or any other product with a similar mechanism of action

• Had a history of gastric or vagus nerve surgery

• Had any clinically significant laboratory abnormalities and medical conditions which were unexplained, or, in the opinion of the investigator, did not allow for safe entry of the subject into the study

• Had contraindications to intramuscular injections (e.g., bleeding disorders or treatment with anticoagulants [except for aspirin])

• Had serious and unstable cardiovascular or respiratory disease, other malignancy or any other condition that would have jeopardized subject safety or confounded the results

• Had a known hypersensitivity to diphtheria toxoid, G17DT, any of its components or any similar compound

• Had any other condition that might have influenced the plasma gastrin level (e.g., achlorhydria, Zollinger-Ellison syndrome)

• Had used of an investigational drug within the previous month

• Had taken treatments that alter the immune response such as radiotherapy, corticosteroids, and antineoplastic drugs (Inhaled corticosteroids were permitted.)

• Had conditions that impaired the immune response (e.g., acquired immune deficiency syndrome)

• Had a history of drug or alcohol abuse within the past year

• Was unable to accept a standard breakfast for dietary reasons

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Biological:
• G17DT
G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.

Drug:
• Omeprazole
Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Advances Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in plasma gastrin level.	Compare basal and meal stimulated plasma gastrin levels before and after treatment with three intramuscular injections of 250 µg G17DT, with and without the concomitant administration of Omeprazole.	up to Day 100	No